Literature DB >> 29935121

Test-retest variability of [11 C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans.

Kelly Smart1, Sylvia M L Cox1, Atsuko Nagano-Saito1, Pedro Rosa-Neto2,3, Marco Leyton1,2, Chawki Benkelfat1,2.   

Abstract

[11 C]ABP688 is a positron emission tomography (PET) radioligand that binds selectively to metabotropic glutamate type 5 receptors (mGluR5). The use of this tracer has identified receptor binding changes in clinical populations, and has been informative in drug occupancy studies. However, previous studies have found significant increases in [11 C]ABP688 binding in the later scan of same-day comparisons, and estimates of test-retest reliability under consistent scanning conditions are not available. The objective of this study was to assess the variability of [11 C]ABP688 binding in healthy people in scans performed at the same time of day. Two [11 C]ABP688 scans were acquired in eight healthy volunteers (6 women, 2 men) using a high-resolution research tomograph (HRRT). Scans were acquired 3 weeks apart with start times between 10:00am and 1:30pm. Mean mGluR5 binding potential (BPND ) values were calculated across cortical, striatal and limbic brain regions. Participants reported on subjective mood state after each scan and blood samples were drawn for cortisol analysis. No significant change in BPND between scans was observed. Variability in BPND values of 11-21% was observed across regions, with the greatest change in the hippocampus and amygdala. Reliability was low to moderate. BPND was not statistically related to scan start time, subjective anxiety, serum cortisol levels, or menstrual phase in women. Overall, [11 C]ABP688 BPND estimates show moderate variability in healthy people. Reliability is fair in cortical and striatal regions, and lower in limbic regions. Future research using this ligand should account for this in study design and analysis.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  [11C]ABP688; metabotropic glutamate receptor type 5; positron emission tomography; test-retest

Mesh:

Substances:

Year:  2018        PMID: 29935121     DOI: 10.1002/syn.22041

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  8 in total

1.  Dysregulation of Decision Making Related to Metabotropic Glutamate 5, but Not Midbrain D3, Receptor Availability Following Cocaine Self-administration in Rats.

Authors:  Stephanie M Groman; Ansel T Hillmer; Heather Liu; Krista Fowles; Daniel Holden; Evan D Morris; Daeyeol Lee; Jane R Taylor
Journal:  Biol Psychiatry       Date:  2020-06-29       Impact factor: 13.382

2.  Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors.

Authors:  Kelly Smart; Sylvia M L Cox; Stephanie G Scala; Maria Tippler; Natalia Jaworska; Michel Boivin; Jean R Séguin; Chawki Benkelfat; Marco Leyton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-09       Impact factor: 9.236

3.  mGluR5 binding changes during a mismatch negativity task in a multimodal protocol with [11C]ABP688 PET/MR-EEG.

Authors:  Christoph W Lerche; Irene Neuner; Cláudia Régio Brambilla; Tanja Veselinović; Ravichandran Rajkumar; Jörg Mauler; Andreas Matusch; Andrej Ruch; Linda Orth; Shukti Ramkiran; Hasan Sbaihat; Nicolas Kaulen; Nibal Yahya Khudeish; Christine Wyss; Karsten Heekeren; Wolfram Kawohl; Elena Rota Kops; Lutz Tellmann; Jürgen Scheins; Frank Boers; Bernd Neumaier; Johannes Ermert; Markus Lang; Stefan Stüsgen; Hans Herzog; Karl-Josef Langen; N Jon Shah
Journal:  Transl Psychiatry       Date:  2022-01-10       Impact factor: 6.222

4.  mGluR5 and GABAA receptor-specific parametric PET atlas construction-PET/MR data processing pipeline, validation, and application.

Authors:  Nicolas Kaulen; Ravichandran Rajkumar; Cláudia Régio Brambilla; Jörg Mauler; Shukti Ramkiran; Linda Orth; Hasan Sbaihat; Markus Lang; Christine Wyss; Elena Rota Kops; Jürgen Scheins; Bernd Neumaier; Johannes Ermert; Hans Herzog; Karl-Joseph Langen; Christoph Lerche; N Jon Shah; Tanja Veselinović; Irene Neuner
Journal:  Hum Brain Mapp       Date:  2022-01-25       Impact factor: 5.038

5.  Differences in mGluR5 Availability Depending on the Level of Social Avoidance in Drug-Naïve Young Patients with Major Depressive Disorder.

Authors:  Jeong-Hee Kim; Yo-Han Joo; Young-Don Son; Hang-Keun Kim; Jong-Hoon Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2022-09-12       Impact factor: 2.989

6.  mGluR5 receptor availability is associated with lower levels of negative symptoms and better cognition in male patients with chronic schizophrenia.

Authors:  Cláudia Régio Brambilla; Tanja Veselinović; Ravichandran Rajkumar; Jörg Mauler; Linda Orth; Andrej Ruch; Shukti Ramkiran; Karsten Heekeren; Wolfram Kawohl; Christine Wyss; Elena Rota Kops; Jürgen Scheins; Lutz Tellmann; Frank Boers; Bernd Neumaier; Johannes Ermert; Hans Herzog; Karl-Josef Langen; N Jon Shah; Christoph Lerche; Irene Neuner
Journal:  Hum Brain Mapp       Date:  2020-03-09       Impact factor: 5.038

7.  mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use.

Authors:  Sylvia M L Cox; Maria Tippler; Natalia Jaworska; Kelly Smart; Natalie Castellanos-Ryan; France Durand; Dominique Allard; Chawki Benkelfat; Sophie Parent; Alain Dagher; Frank Vitaro; Michel Boivin; Robert O Pihl; Sylvana Côté; Richard E Tremblay; Jean R Séguin; Marco Leyton
Journal:  Neuropsychopharmacology       Date:  2020-05-15       Impact factor: 7.853

Review 8.  A Review of Molecular Imaging of Glutamate Receptors.

Authors:  Jong-Hoon Kim; János Marton; Simon Mensah Ametamey; Paul Cumming
Journal:  Molecules       Date:  2020-10-16       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.